Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

By Zhi-xiang Shen, Guo-Qiang Chen, J. Ni, Xiu-Shong Li, S. Xiong, Qian Qiu, Junxia Zhu, Wei-Yao Tang, Guan-lin Sun, Kan-Qi Yang and 10 more. 1997

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery (2013, neutral): “comparison to de novo design[4-11].”
Upsides and Downsides of Reactive Oxygen Species for Cancer: The Roles of Reactive Oxygen Species in Tumorigenesis, Prevention, and Therapy (2012, unknown): “As 2 O 3 has the ability to induce superoxide production in cancer cells (147, 234, 242, 277).”
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia (2003, background): “It has been reported that arsenic trioxide (As2O3) is effective in patients with APL who develop recurrent disease after treatment with ATRA.(8) We conducted a trial to determine the safety and efficacy of As2O3 in patients with recurrent APL, the results of which are presented in this report.”